Cargando…

Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps

The purpose of this study was to evaluate the efficacy of intravitreal aflibercept for active polypoidal choroidal vasculopathy (PCV) without active polyps and to identify prognostic factors. We enrolled 40 eyes from 40 patients who manifested PCV with exudation but without active polyps after prior...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang Eun, Jang, Jun Won, Kang, Se Woong, Park, Kyu Hyung, Lee, Dong Won, Kim, Jae Hui, Bae, KunHo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365522/
https://www.ncbi.nlm.nih.gov/pubmed/30728380
http://dx.doi.org/10.1038/s41598-018-37523-5
_version_ 1783393436886368256
author Lee, Sang Eun
Jang, Jun Won
Kang, Se Woong
Park, Kyu Hyung
Lee, Dong Won
Kim, Jae Hui
Bae, KunHo
author_facet Lee, Sang Eun
Jang, Jun Won
Kang, Se Woong
Park, Kyu Hyung
Lee, Dong Won
Kim, Jae Hui
Bae, KunHo
author_sort Lee, Sang Eun
collection PubMed
description The purpose of this study was to evaluate the efficacy of intravitreal aflibercept for active polypoidal choroidal vasculopathy (PCV) without active polyps and to identify prognostic factors. We enrolled 40 eyes from 40 patients who manifested PCV with exudation but without active polyps after prior treatment with photodynamic therapy (PDT) and/or anti-vascular endothelial growth factor (VEGF) other than aflibercept. Participants were initially given three consecutive intravitreal injections of aflibercept at 1-month intervals, followed by injections every 2 months in the maintenance phase. Spectral-domain optical coherence tomographic and indocyanine green angiographic features were assessed to determine associations between anatomical parameters and visual outcomes 14 months later. Mean visual acuity improved from 61.5 ± 11.1 letters at baseline to 68.1 ± 13.6 letters at 14 months (P = 0.001). Better vision and a smaller branching vascular network at baseline and 1 month after three monthly injections (visit 4) were associated with better final vision (P < 0.001). The presence of an inner retinal cyst at visit 4 was significantly related to worse final vision (P = 0.011). Intravitreal aflibercept improved the visual and anatomical outcomes of PCV with exudation from BVN after pre-treatment with PDT and/or anti-VEGF other than aflibercept. Better vision, smaller lesion size, and absence of an inner retinal cyst after induction therapy may predict better visual outcome.
format Online
Article
Text
id pubmed-6365522
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-63655222019-02-08 Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps Lee, Sang Eun Jang, Jun Won Kang, Se Woong Park, Kyu Hyung Lee, Dong Won Kim, Jae Hui Bae, KunHo Sci Rep Article The purpose of this study was to evaluate the efficacy of intravitreal aflibercept for active polypoidal choroidal vasculopathy (PCV) without active polyps and to identify prognostic factors. We enrolled 40 eyes from 40 patients who manifested PCV with exudation but without active polyps after prior treatment with photodynamic therapy (PDT) and/or anti-vascular endothelial growth factor (VEGF) other than aflibercept. Participants were initially given three consecutive intravitreal injections of aflibercept at 1-month intervals, followed by injections every 2 months in the maintenance phase. Spectral-domain optical coherence tomographic and indocyanine green angiographic features were assessed to determine associations between anatomical parameters and visual outcomes 14 months later. Mean visual acuity improved from 61.5 ± 11.1 letters at baseline to 68.1 ± 13.6 letters at 14 months (P = 0.001). Better vision and a smaller branching vascular network at baseline and 1 month after three monthly injections (visit 4) were associated with better final vision (P < 0.001). The presence of an inner retinal cyst at visit 4 was significantly related to worse final vision (P = 0.011). Intravitreal aflibercept improved the visual and anatomical outcomes of PCV with exudation from BVN after pre-treatment with PDT and/or anti-VEGF other than aflibercept. Better vision, smaller lesion size, and absence of an inner retinal cyst after induction therapy may predict better visual outcome. Nature Publishing Group UK 2019-02-06 /pmc/articles/PMC6365522/ /pubmed/30728380 http://dx.doi.org/10.1038/s41598-018-37523-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lee, Sang Eun
Jang, Jun Won
Kang, Se Woong
Park, Kyu Hyung
Lee, Dong Won
Kim, Jae Hui
Bae, KunHo
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
title Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
title_full Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
title_fullStr Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
title_full_unstemmed Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
title_short Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
title_sort intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365522/
https://www.ncbi.nlm.nih.gov/pubmed/30728380
http://dx.doi.org/10.1038/s41598-018-37523-5
work_keys_str_mv AT leesangeun intravitrealafliberceptforactivepolypoidalchoroidalvasculopathywithoutactivepolyps
AT jangjunwon intravitrealafliberceptforactivepolypoidalchoroidalvasculopathywithoutactivepolyps
AT kangsewoong intravitrealafliberceptforactivepolypoidalchoroidalvasculopathywithoutactivepolyps
AT parkkyuhyung intravitrealafliberceptforactivepolypoidalchoroidalvasculopathywithoutactivepolyps
AT leedongwon intravitrealafliberceptforactivepolypoidalchoroidalvasculopathywithoutactivepolyps
AT kimjaehui intravitrealafliberceptforactivepolypoidalchoroidalvasculopathywithoutactivepolyps
AT baekunho intravitrealafliberceptforactivepolypoidalchoroidalvasculopathywithoutactivepolyps